Multi-drug Resistant Tuberculosis Clinical Trial
Official title:
Post-marketing Registry to Assess Usage Information, Safety and Effectiveness of Deltyba® Tablets in Korean Patients With Pulmonary Multi-drug Resistant Tuberculosis (MDR-TB)
NCT number | NCT03470233 |
Other study ID # | 242-402-00005 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | May 25, 2017 |
Est. completion date | June 21, 2021 |
Verified date | August 2021 |
Source | Korea Otsuka Pharmaceutical Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Deltyba Registry aims to collect the usage information of Deltyba which could be a factor of developing resistance in actual clinical settings.
Status | Completed |
Enrollment | 149 |
Est. completion date | June 21, 2021 |
Est. primary completion date | June 21, 2021 |
Accepts healthy volunteers | |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria 1. Patients who are prescribed Deltyba® per prescribing information (PI) for the purpose of treatment can be included in the registry. Exclusion Criteria 1. Patients with known hypersensitivity to Delamanid or any excipients of Deltyba® 2. Patients whose serum albumin < 2.8 g/dL 3. Patients taking medicinal products that are strong inducers of CYP3A (e.g. carbamazepine). 4. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medicinal product. |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Ulsan University Hospital | Ulsan | |
Korea, Republic of | Pusan National University Yangsan Hospital | Yangsan |
Lead Sponsor | Collaborator |
---|---|
Korea Otsuka Pharmaceutical Co., Ltd. |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dose of Deltyba | Mean values | for 24 weeks | |
Primary | Administration duration of Deltyba | Mean values | for 24 weeks | |
Primary | Compliance of Deltyba | percentages (%) of subjects who take Deltyba in excess of 80% compared with the amount of Deltyba prescribed by investigators | for 24 weeks | |
Secondary | Incidences of AEs | Numbers (n) of subjects with AEs | at least 1 month after the final administration or premature discontinuation | |
Secondary | Incidences of ADRs | Percentages (%) of subjects with ADRs | at least 1 month after the final administration or premature discontinuation | |
Secondary | Incidences of AEs in special populations | Percentages (%) of subjects with AEs in special populations, such as the elderly, pregnant women, and patients with hepatic or renal disorder | at least 1 month after the final administration or premature discontinuation | |
Secondary | Incidences of ADRs in special populations | Number (n) of subjects with ADRs in special populations, such as the elderly, pregnant women, and patients with hepatic or renal disorder | at least 1 month after the final administration or premature discontinuation | |
Secondary | Observed cases of resistance to Deltyba after completing the administration (Week 24) or premature discontinuation of Deltyba, Observed cases of resistance to Deltyba after 6 months of administration or discontinuation of administration | Numbers (n) of subjects who developed drug resistance as determined by drug susceptibility testing (DST) to Deltyba in subjects who resulted in positive in sputum test after termination of the administration or were reverter during the course of treatment | after completing the administration (Week 24) or premature discontinuation of Deltyba | |
Secondary | Response rate | Number (n) of treatment responders (sustained converters plus new converters), Numbers (n) of sustained converters, new converters, non-converters, and reverters | at 24 week (at the end of Deltyba administration) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03057756 -
Treatment of Tuberculosis Multidrug Resistance Treatment of Tuberculosis Multidrug Resistance
|
||
Completed |
NCT04207112 -
Economic Evaluation of New MDR TB Regimens
|
Phase 2/Phase 3 | |
Completed |
NCT03000517 -
PK of Levofloxacin in MDR-TB Patients
|
N/A | |
Completed |
NCT03830671 -
The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB
|
Phase 4 | |
Withdrawn |
NCT01600963 -
A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis
|
Phase 3 | |
Recruiting |
NCT03575299 -
Clinical Study on Adoptive Treatment of MDR-TB With Allogeneic γδT Cells
|
Phase 1 | |
Recruiting |
NCT03827811 -
Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis-PandrTB Tuberculosis
|
||
Completed |
NCT04342598 -
Case Control Study of Vitamin D Status and Adult Multidrug-resistant Pulmonary Tuberculosis in Maharashtra, India
|
||
Completed |
NCT04309656 -
A Study in Two Panels of Healthy Adult Participants to Assess Single-Dose Immediate-Release and Single-Dose Dispersible Formulations of Pretomanid
|
Phase 1 | |
Completed |
NCT03822156 -
Clinical Analysis of the Patients With Cavitary Pulmonary TB and Endobronchial TB in the PPM-UUH Cohort
|
||
Completed |
NCT00425113 -
Metronidazole for Pulmonary Tuberculosis (South Korea)
|
Phase 2 | |
Active, not recruiting |
NCT04081077 -
PRACTECAL-PKPD Sub Study
|
Phase 2/Phase 3 | |
Recruiting |
NCT04397536 -
New Genomic Techniques and Management of Multidrug-resistant Tuberculosis
|
||
Completed |
NCT00691392 -
Linezolid Pharmacokinetics (PK) in Multi-Drug Resistant (MDR)/Extensively-Drug Resistant (XDR) Tuberculosis (TB)
|
Phase 1/Phase 2 | |
Completed |
NCT00664313 -
TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB
|
Phase 1/Phase 2 |